Similar articles for PMID: 29298302

Year	Number of Results
2006	1
2007	4
2008	1
2009	4
2010	4
2011	3
2012	4
2013	5
2014	6
2015	15
2016	7
2017	9
2018	9
2019	11
2020	2
2021	1
2022	1
2024	0

1

Characterization of a candidate tetravalent vaccine based on 2'-O-methyltransferase mutants.

Züst R, Li SH, Xie X, Velumani S, Chng M, Toh YX, Zou J, Dong H, Shan C, Pang J, Qin CF, Newell EW, Shi PY, Fink K. Züst R, et al. PLoS One. 2018 Jan 3;13(1):e0189262. doi: 10.1371/journal.pone.0189262. eCollection 2018. PLoS One. 2018. PMID: 29298302 Free PMC article.

2

Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.

Osorio JE, Brewoo JN, Silengo SJ, Arguello J, Moldovan IR, Tary-Lehmann M, Powell TD, Livengood JA, Kinney RM, Huang CY, Stinchcomb DT. Osorio JE, et al. Am J Trop Med Hyg. 2011 Jun;84(6):978-87. doi: 10.4269/ajtmh.2011.10-0592. Am J Trop Med Hyg. 2011. PMID: 21633037 Free PMC article.

3

Rational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques.

Züst R, Dong H, Li XF, Chang DC, Zhang B, Balakrishnan T, Toh YX, Jiang T, Li SH, Deng YQ, Ellis BR, Ellis EM, Poidinger M, Zolezzi F, Qin CF, Shi PY, Fink K. Züst R, et al. PLoS Pathog. 2013;9(8):e1003521. doi: 10.1371/journal.ppat.1003521. Epub 2013 Aug 1. PLoS Pathog. 2013. PMID: 23935499 Free PMC article.

4

Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.

George SL, Wong MA, Dube TJ, Boroughs KL, Stovall JL, Luy BE, Haller AA, Osorio JE, Eggemeyer LM, Irby-Moore S, Frey SE, Huang CY, Stinchcomb DT. George SL, et al. J Infect Dis. 2015 Oct 1;212(7):1032-41. doi: 10.1093/infdis/jiv179. Epub 2015 Mar 19. J Infect Dis. 2015. PMID: 25791116 Free PMC article. Clinical Trial.

5

Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.

Poddar A, Ramasamy V, Shukla R, Rajpoot RK, Arora U, Jain SK, Swaminathan S, Khanna N. Poddar A, et al. BMC Biotechnol. 2016 Jun 14;16(1):50. doi: 10.1186/s12896-016-0280-y. BMC Biotechnol. 2016. PMID: 27301568 Free PMC article.

6

Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.

Barban V, Mantel N, De Montfort A, Pagnon A, Pradezynski F, Lang J, Boudet F. Barban V, et al. J Virol. 2018 May 29;92(12):e00440-18. doi: 10.1128/JVI.00440-18. Print 2018 Jun 15. J Virol. 2018. PMID: 29593041 Free PMC article.

7

The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.

Prompetchara E, Ketloy C, Keelapang P, Sittisombut N, Ruxrungtham K. Prompetchara E, et al. Asian Pac J Allergy Immunol. 2015 Sep;33(3):182-8. doi: 10.12932/AP0508.33.3.2015. Asian Pac J Allergy Immunol. 2015. PMID: 26342114 Free article.

8

Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.

Magnani DM, Silveira CGT, Ricciardi MJ, Gonzalez-Nieto L, Pedreño-Lopez N, Bailey VK, Gutman MJ, Maxwell HS, Domingues A, Costa PR, Ferrari L, Goulart R, Martins MA, Martinez-Navio JM, Fuchs SP, Kalil J, Timenetsky MDC, Wrammert J, Whitehead SS, Burton DR, Desrosiers RC, Kallas EG, Watkins DI. Magnani DM, et al. J Virol. 2017 Oct 27;91(22):e00867-17. doi: 10.1128/JVI.00867-17. Print 2017 Nov 15. J Virol. 2017. PMID: 28878078 Free PMC article. Clinical Trial.

9

Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.

Sáez-Llorens X, Tricou V, Yu D, Rivera L, Tuboi S, Garbes P, Borkowski A, Wallace D. Sáez-Llorens X, et al. Lancet Infect Dis. 2017 Jun;17(6):615-625. doi: 10.1016/S1473-3099(17)30166-4. Epub 2017 Mar 30. Lancet Infect Dis. 2017. PMID: 28365225 Clinical Trial.

10

An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

Urakami A, Ngwe Tun MM, Moi ML, Sakurai A, Ishikawa M, Kuno S, Ueno R, Morita K, Akahata W. Urakami A, et al. J Virol. 2017 Nov 14;91(23):e01181-17. doi: 10.1128/JVI.01181-17. Print 2017 Dec 1. J Virol. 2017. PMID: 28956764 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

78 results

Results by year